Serum-and glucocorticoid-regulated kinase 1 (SGK1) is an AGC kinase that regulates membrane sodium channel expression in renal tubular cells in an mTORC2-dependent manner. We hypothesized that SGK1 might represent a novel mTORC2-dependent regulator of T cell differentiation and function. Here we demonstrate that upon activation by mTORC2, SGK1 promoted T H 2 differentiation by negatively regulating the NEDD4-2 E3 ligase-mediated destruction of transcription factor JunB. Simultaneously, SGK1 repressed the production of interferon-γ (IFN-γ) by controlling the expression of the long isoform of transcription factor TCF-1. Consistent with these findings, mice with a selective deletion of SGK1 in T cells were resistant to experimentally induced asthma, generated robust amounts of IFN-γ in response to viral infections and more readily rejected tumors.
INTRODUCTION
AGC kinases are serine/threonine protein kinases that are broadly involved in regulating numerous aspects of cell physiology, including growth, survival and metabolism 1 . The serum-and glucocorticoid-regulated kinase 1 (SGK1) is an AGC kinase that is activated by sequential phosphorylation of two highly conserved regulatory motifs. The T-loop domain is phosphorylated at threonine 256 by the kinase PDK1 (ref. 2 ), and the hydrophobic motif is phosphorylated at serine 422 by mTORC2 (refs. 3, 4 ). Compared to other AGC kinases that are also downstream of mTOR, such as Akt and S6 kinase, relatively little is known about SGK1. Downstream targets of SGK1 include E3 ubiquitin ligases such as NEDD4-2 (refs. 5, 6 ), transcription factors such as Foxo 7, 8 , and other kinases like GSK-3β 9 . In the kidney, SGK1 phosphorylates and inhibits NEDD4-2 to prevent degradation of the epithelial Na + channel, thus allowing sodium to be reclaimed in the urine when serum concentrations of sodium are low 5, 10, 11 . Recently, it has been shown that SGK1 mRNA is upregulated by sodium in lymphocytes, and that mice that are fed a high salt diet develop more severe T H 17-mediated autoimmune encephalomyelitis 12, 13 . Loss of SGK1 in T cells leads to a selective defect in pathogenic T H 17 differentiation, due to decreased expression of the interleukin 23 (IL-23) receptor 12 . The role of SGK1 in other T cell lineages, however, has yet to be determined.
We became interested in SGK1 because it is a downstream target of mTOR, which serves as a critical node in a highly conserved signaling pathway that integrates multiple inputs from the environment 14, 15 . In the immune system, mTOR integrates various signals, such as cytokines and costimulatory molecules, to influence T cell differentiation 15 . mTOR can associate with two distinct protein complexes (mTORC1 and mTORC2) to drive the selective differentiation of CD4 + T cells. Genetic deletion of mTOR in CD4 + T cells has shown that loss of both mTORC1 and mTORC2 signaling results in a default T regulatory (Treg) phenotype upon T cell activation 16, 17 . Loss of either mTORC1 or mTORC2 leads to selective deficits in distinct T cell lineages. For example, genetic deletion of the mTORC2 adapter protein Rictor in CD4 + T cells results in defective T H 2 differentiation, characterized by an inability to produce IL-4 (refs. 18, 19 ). Despite the critical role of mTOR in regulating T effector and Treg cell differentiation, the precise downstream targets of mTOR that control differentiation into distinct helper T cell subsets have yet to be elucidated.
Because SGK1 is a downstream target of mTORC2, we hypothesized that it might be involved in mTORC2 regulation of T H 2 lineage commitment. To this end, we generated mice in which SGK1 was selectively deleted in T cells by crossing Sgk1 fl/fl mice 11 with Cd4-Cre expressing mice (hereafter referred to as T-Sgk1 −/− mice). We show that loss of SGK1 led to decreased production of IL-4 and inappropriate release of interferon-γ (IFN-γ) under T H 2 polarizing conditions in vitro. In a mouse model of allergic asthma, we found that loss of SGK1 resulted in diminished T H 2 responses and protection against disease. Mechanistically, we show that SGK1 promoted T H 2 differentiation by preventing ubiquitination and destruction of the transcription factor JunB by NEDD4-2 and its adaptor protein Ndfip. Alternatively, we found that T-Sgk1 −/− mice produced increased amounts of IFN-γ under T H 1 polarizing conditions in vivo, which was associated with both stronger anti-tumor and anti-viral immune responses. The ability of SGK1 to inhibit T H 1 differentiation was mediated in part by its ability to regulate the expression of the long isoform of TCF-1 via β-catenin and GSK-3β. Overall, our findings define distinct signaling pathways downstream of SGK1 that provide new evidence as to how mTOR controls helper T cell differentiation.
RESULTS

SGK1 is activated upon antigen recognition in T cells
Sgk1 RNA is expressed in resting naïve T cells ( Supplementary Fig. 1a ). We wanted to determine whether SGK1 is activated upon T cell stimulation by measuring the phosphorylation of the SGK1 substrate N-myc downregulated gene 1 (p-NDRG1 T346) 20 . Activation of T cells led to an increase in SGK1 activity (Fig. 1a) . The kinetics of SGK1 activation paralleled the mTORC2-dependent activation of Akt (p-Akt S473). Next, we investigated whether SGK1 activity was modulated by polarizing cytokines upon T cell activation. Consistent with a recent report 12 , SGK1 mRNA was expressed under all polarizing conditions in vitro, but expression was highest under T H 17 conditions ( Supplementary Fig. 1b) . Interestingly, we found that SGK1 activity was acutely induced to a similar degree under all polarizing conditions (Fig. 1b) .
In light of the role of mTOR in regulating SGK1 activity in HEK293T, MCF-7 and HeLa cells 3, 21 , we sought to determine whether SGK1 was also activated in an mTOR-dependent manner in T cells ( Supplementary Fig. 2a ). Phosphorylation of NDRG1 increased upon T cell stimulation, but this effect was abrogated in the presence of the mTOR kinase inhibitor PP242 (Fig. 1c) 22 . Consistent with these results, inhibition of Akt phosphorylation (p-Akt S473) was also observed, indicating successful blockade of mTORC2 activity 23, 24, 25 (Fig.  1c) . Likewise, the deletion of the mTORC2 component Rictor mitigated both Akt and SGK1 activation (Fig. 2a, Supplementary Fig. 2b,c) . Having established that SGK1 signaling is mTORC2-dependent in T cells, we wanted to determine if SGK1 might function downstream of mTORC2 to regulate helper T cell differentiation. To address this question, mice were generated in which SGK1 was selectively deleted in T cells by breeding Sgk1 fl/fl mice 11 with mice transgenic for Cre under control of the Cd4 promoter and enhancer regions (T-Sgk1 −/− mice) ( Supplementary Fig. 1a ). Upon stimulation, phosphorylation of NDRG1 was markedly decreased in T-Sgk1 −/− CD4 + T cells (Fig. 2a) . Alternatively, the selective deletion of SGK1 in T cells did not affect Akt or S6 phosphorylation ( Supplementary Fig.  2b ,c).
The role of SGK1 in the maturation of peripheral T cells has never been described. Thymic development was essentially not different between wild-type and T-Sgk1 −/− mice ( Supplementary Fig. 3a ) and there were no differences in the percent of CD3 + , B220 + , CD4 + and CD8 + cells in the spleen and lymph nodes compared to wild-type mice (Fig. 2b-e) . Subtle differences in absolute T cell numbers and expression of activation markers were observed ( Supplementary Fig. 3b-g ). Finally there was a slight increase in Foxp3 + T cells in the spleens of T-Sgk1 −/− mice when compared to wild-type mice (6.23% vs 7.50%) however these differences were not observed in the lymph nodes ( Supplementary Fig. 3h ). T-Sgk1 −/− CD4 + T cells displayed a slightly reduced rate of proliferation (Fig. 2f) . Nevertheless, TSgk1 −/− CD4 + T cells produce similar amounts of IL-2 compared to wild-type cells (Fig. 2g) . Thus, the deletion of SGK1 does not greatly impact the composition of the peripheral T cell compartment.
SGK1 regulates T H 1 and T H 2 differentiation
In light of the ability of mTORC2 to regulate T H 2 generation 18, 19 , we wanted to determine whether loss of SGK1 affected T H 1 and T H 2 differentiation. CD4 + T cells from wild-type and T-Sgk1 −/− mice were polarized under T H 0, T H 1, or T H 2 conditions and interrogated for IL-4 production. As expected, wild-type T cells polarized under T H 2 conditions produced IL-4 upon re-challenge (Fig. 3a) . However, T cells from T-Sgk1 −/− mice failed to produce robust amounts of IL-4. Furthermore, loss of SGK1 resulted in decreased production of the T H 2 cytokines IL-5 and IL-13 (Fig. 3b,c) .
Next, we examined the ability of T cells from T-Sgk1 −/− mice to produce IFN-γ and to be polarized to T H 1 effector cells. Without any polarizing cytokines, T cells from C57BL/6 mice will preferentially differentiate into T H 1 cells (Fig. 3d) . CD4 + T cells from both wildtype and T-Sgk1 −/− mice activated and cultured under non-polarizing (T H 0) or T H 1 polarizing conditions led to the generation of IFN-γ producing cells. However, T cells from T-Sgk1 −/− mice robustly expressed IFN-γ even when they were differentiated under T H 2 conditions (Fig. 3d) . Thus, T cells lacking SGK1 fail to produce IL-4, IL-5, and IL-13, but instead inappropriately produce IFN-γ under T H 2 polarizing conditions. Consistent with recent studies (ref. 12, 13 ), SGK1 does not affect T H 17 polarization ( Supplementary Fig. 4 ).
Next, we examined the lineage-specific transcription factors T-bet and GATA-3. As expected, wild-type T cells cultured under T H 1 conditions expressed abundant T-bet, while cells cultured under T H 2 conditions robustly expressed GATA-3 (Fig. 3e) . Alternatively, T cells derived from T-Sgk1 −/− mice expressed abundant T-bet when cultured under either T H 1 or T H 2 conditions. Such cells also failed to express GATA-3 under T H 2 polarizing conditions. Overall, these observations demonstrate a role for SGK1 in reciprocally regulating T H 1 and T H 2 differentiation. During CD4 + T cell effector differentiation, SGK1 activation simultaneously enhances IL-4 production and inhibits IFN-γ production.
SGK1 regulates T H 2 differentiation by stabilizing JunB
We sought to define a biochemical mechanism by which SGK1 regulates T H 1 and T H 2 differentiation. We did not observe a defect in IL-4 receptor expression or IL-4-induced STAT6 phosphorylation in the absence of SGK1 (data not shown). Previous studies on the role of SGK1 in renal epithelial cells have demonstrated that SGK1 negatively regulates the HECT-type E3 ligase by phosphorylation at serine 342 and serine 448 (refs. 5, 10 ) . A closely related homolog of NEDD4-2 is the ubiquitin ligase Itch, which has been shown to interact with the NEDD4 family-interacting protein 1 (Ndfip1) adapter protein to mediate polyubiquitination of JunB 26, 27 . JunB has been shown to be essential for T H 2 development 26, 28 . We sought to determine if the defect in T H 2 differentiation that we observed in T-Sgk1 −/− mice could be in part due to increased ubiquitination and destruction of JunB by NEDD4-2. As previously shown 28 , JunB abundance was higher in wild-type T cells cultured under T H 2 conditions compared to those cultured under T H 1 conditions (Fig.  4a) . In SGK1-deficient T cells, we observed that JunB protein abundance was decreased under both T H 1 and T H 2 polarizing conditions (Fig. 4a) . These findings correlated with the phosphorylation status of NEDD4-2 at S342. That is, inhibition of NEDD4-2 (as measured by p-NEDD4-2 S342) was greatest under T H 2 conditions and decreased in the absence of SGK1 (Fig. 4a) .
We next investigated the ability of SGK1 to regulate NEDD4-2 in vivo. To this end, we adoptively transferred congenically marked Thy1.1 + , ovalbumin (OVA)-specific CD4 + T cells from wild-type or T-Sgk1 −/− mice into naïve hosts that were subsequently immunized with OVA in alum to induce a T H 2 response. Similar to the in vitro results, we observed p-NEDD4-2 S342 phosphorylation and inhibition upon stimulation of wild-type adoptively transferred cells (Fig. 4b) . By contrast, NEDD4-2 was not phosphorylated and inhibited in T-Sgk1 −/− adoptively transferred cells.
Our data are consistent with the hypothesis that NEDD4-2 degrades JunB protein in T cells lacking SGK1 even under T H 2 conditions, both in vitro and in vivo. To further test this hypothesis, wild-type and T-Sgk1 −/− T CD4 + cells were activated under T H 2 conditions in the presence of the proteasome inhibitor MG132. JunB abundance was markedly decreased in the T cells lacking SGK1 when compared to the wild-type T cells (Fig. 4c) . However, expression of JunB protein was restored in T-Sgk1 −/− cells in the presence of MG132, suggesting that Jun B is expressed in T-Sgk1 −/− T cells but is subsequently degraded. To confirm that JunB degradation was due to increased ubiquitination we immunoprecipitated JunB in wild-type and T-Sgk1 −/− CD4+ T cells and immunoblotted for ubiquitin. We found that JunB was not ubiquitinated under T H 2 conditions in wild-type cells, but JunB ubiquitination was markedly enhanced in the absence of SGK1 (Fig. 4d) .
Next, we wanted to determine whether we could rescue the ability of T-Sgk1 −/− CD4 + T cells to make IL-4 under T H 2 conditions by knocking down NEDD4-2 or Ndfip using siRNA. Knocking down either NEDD4-2 or Ndfip led to partial rescue of IL-4 production in the T-Sgk1 −/− T H 2 polarized T cells (Fig. 4e) . Knockdown was confirmed by measuring the expression of NEDD4-2 and Ndfip mRNA ( Supplementary Fig. 5a ,b). Additionally, NEDD4-2 knockdown was confirmed at the protein level, which correlated with the reaccumulation of JunB protein (Fig. 4f ). It was difficult to confirm knockdown of Ndfip at the protein level because the available antibodies are not robust, however knockdown of Ndfip also resulted in the re-accumulation of JunB protein (data not shown). Altogether, these results suggest that SGK1 activation promotes T H 2 differentiation in part by negatively regulating E3 ligases that target JunB for destruction.
T-Sgk1 −/− mice are resistant to Th2-mediated asthma
Since we had defined the role of SGK1 in regulating the differentiation of helper T cells in vitro, we wanted to confirm this paradigm in an in vivo model. We chose to study the OVAalum allergic asthma model because T H 2 cells are involved in the early pathogenesis of this disease 29 . Therefore, we hypothesized that T-Sgk1 −/− mice would be resistant to allergic asthma. Wild-type mice mounted a stereotypic T H 2 response to this allergic stimulus, characterized by IL-4 in bronchoalveolar lavage (BAL) and IgE in serum. However, BAL and serum from T-Sgk1 −/− mice contained significantly less IL-4 and IgE ( Supplementary  Fig. 6a,b) . Alternatively, we detected OVA-specific IgG2a, characteristic of a T H 1 response in the serum of T-Sgk1 −/− mice ( Supplementary Fig. 6c ). Along these lines, lung lymphocytes from T-Sgk1 −/− mice inappropriately produced IFN-γ when stimulated ex vivo ( Supplementary Fig. 6d ). Thus in this in vivo model of T H 2-mediated inflammation, loss of SGK1 in T cells abrogated the T H 2 response and instead produced an inappropriate T H 1 response to an allergic stimulus.
In light of these findings we wanted to determine if deleting SGK1 in T cells could prevent allergen-induced lung pathology. To this end we challenged wild-type and T-Sgk1 −/− mice with house dust mite (HDM) extract. Similar to our findings in the OVA-alum adjuvant model, we observed a marked decrease in the T H 2 response of T-Sgk1 −/− mice when challenged with HDM extract. Expression of IL-4, IL-13 and IL-5 in the lungs of T-Sgk1 −/− mice was markedly diminished when compared to wild-type mice ( Fig. 5a-c) . Likewise, we observed a decrease in the expression of these cytokines by CD4 + T cells in the mediastinal lymph nodes of T-Sgk1 −/− mice ( Fig. 5d-g ). We observed a significant decrease in the absolute number of CD4 + T cells in the lymph nodes of T-Sgk1 −/− mice, however, the there was no significant decrease observed in the lungs and BAL fluid between wild-type and TSgk1 −/− mice ( Supplementary Fig. 6e ,f). Consistent with our model, CD4 + T cells in the lungs, BAL and lymph nodes of T-Sgk1 −/− mice produced significantly more IFN-γ compared to wild-type mice (Fig. 5h,i) . Furthermore, the T-Sgk1 −/− mice displayed decreased total IgE, in addition to decreased HDM-specific IgE and IgG1 ( Fig. 5j-l) . Finally, the lungs of the T-Sgk1 −/− mice demonstrated markedly decreased goblet cell hyperplasia and decreased peribronchiolar and perivascular inflammation when compared to the lungs of the wild-type mice ( Fig. 5m-q) . Thus, loss of SGK1 in T cell protects against allergen-induced T H 2-mediated lung disease.
SGK1 negatively regulates IFN-γ production via TCF-1
The SGK1-NEDD4-2-Ndfip-JunB axis provides a selective mechanism as to why TSgk1 −/− CD4 + T cells do not differentiate towards a T H 2 phenotype. However, it does not adequately explain why CD4 + T cells produce IFN-γ under T H 2 conditions in the absence of SGK1. It has previously been reported that the glycogen synthase kinase-3β (GSK-3β) is inhibited by the AGC kinases Akt and SGK1 (ref. 9 ). In turn, GSK-3β phosphorylates β-catenin and targets this protein for degradation 30, 31 . We observed a marked decrease in expression of β-catenin in T-Sgk1 −/− T cells (Fig. 6a) . β-catenin is critical during T H 2 differentiation because it promotes early GATA-3 expression by binding at the proximal promoter 32 . In the absence of SGK1, GSK-3β remains highly active and thus there is very little total β-catenin. On the other hand, inhibiting GSK-3β in the T-Sgk1 −/− T cells with LiCl leads to an increase in total β-catenin (Fig. 6a ).
The transcription factor T cell factor 1 (TCF-1) is both a downstream target of β-catenin and a transcriptional co-activator with β-catenin [31] [32] [33] . Similar to T-Sgk1 −/− mice, mice deficient in TCF-1 produce more IFN-γ even under T H 2 polarizing conditions 32 . Specifically, the long isoforms of TCF-1 contain an additional β-catenin binding domain, and these long isoforms promote T H 2 polarization by increasing expression of GATA-3 and repressing expression of IFN-γ 32 . We hypothesized that there would be decreased expression of the long form of TCF-1 in the T cells lacking SGK1. Wild-type and T-Sgk1 −/− CD4 + T cells were polarized under T H 1 and T H 2 conditions and assayed for TCF-1 protein. We found that the long isoforms of TCF-1 were decreased in T-Sgk1 −/− under both T H 1 and T H 2 polarizing conditions, but there was no difference in expression of the short isoforms of this protein (Fig. 6b) .
To determine if SGK1 regulates TCF-1 expression at the transcriptional level, we designed primers that flank the β-catenin binding domain to specifically detect the long isoform of TCF-1. In the absence of SGK1, we observed decreased transcription of the long isoforms of TCF-1 at 72 h post-TCR activation, and a complete absence of transcripts at 8 days poststimulation (Fig. 6c) . To further test this hypothesis, we sought to rescue the phenotype of T-Sgk1 −/− CD4 + T cells by retroviral transduction with a vector encoding the long isoform of TCF-1 (FL-TCF-1) and a human CD8 reporter (Fig. 6d) . We sorted transduced cells for human CD8, then restimulated the cells and assayed for the production of IFN-γ by intracellular staining. Wild-type T cells polarized under T H 2 conditions failed to express IFN-γ. T cells from the T-Sgk1 −/− mice, transduced with the empty vector (EV), expressed significant amounts of IFN-γ under T H 2 conditions. Alternatively, IFN-γ expression was mitigated when the T-Sgk1 −/− T cells were transfected with FL-TCF-1 (Fig. 6d) . These data support a model whereby under T H 2 conditions SGK1 inhibits the GSK-3β-mediated degradation of β-catenin, leading in turn to increased expression of the long form of TCF-1 and inhibition of IFN-γ ( Supplementary Fig. 7 ).
T-Sgk1 −/− mice mount robust T H 1-mediated immune responses
The ability of SGK1 to regulate T H 2 responses is in part due to its ability to negatively regulate IFN-γ. We wondered whether we would also see an increase in IFN-γ in vivo under strongly polarizing T H 1 conditions in the T-Sgk1 −/− mice. To this end, congenically marked Thy1.1 + , OVA-specific wild-type and T-Sgk1 −/− CD4 + T cells were adoptively transferred into Thy1.2 + wild-type mice that were infected intravenously with OVA-expressing vaccinia virus (Vac-OVA) which induces robust T H 1 immune responses. Vaccinia infection led to a marked increase in the numbers of OVA-specific IFN-γ producing cells from wild-type mice. However, the T H 1 response by the T cells from the Sgk1 −/− mice demonstrated an increase in both the percentage of IFN-γ producing cells and the amount of IFN-γ produced on a per cell basis (Fig. 7a) . To confirm this observation, we challenged wild-type and TSgk1 −/− mice with the PR8 strain of influenza virus, which also promotes a strong T H 1-mediated immune response. Similar to what we observed for vaccinia virus, CD4 + T cells from T-Sgk1 −/− mice produced more IFN-γ in response to influenza virus infection compared to wild-type mice (Fig. 7b) .
To further assess the T H 1 response by T-Sgk1 −/− cells in vivo we employed a model of T H 1-mediated tumor rejection, since T H 1-polarized CD4 + T cells have previously been shown to have an important role in anti-tumor immunity 34 . To address this hypothesis, we injected wild-type and T-Sgk1 −/− mice with 2 × 10 5 B16 melanoma cells intravenously, and harvested lungs 21 days later. Loss of SGK1 in T cells resulted in less than half as many lung tumors as compared to wild-type mice (Fig. 7c, Supplementary Fig. 8 ). While it is quite possible that the decrease in tumor burden could have been promoted by CD8 + T cells, it is clear that the more effective response by the T-Sgk1 −/− mice was associated with an increase in CD4 + IFN-γ producing T cells in the lungs (Fig. 7d) . Next, we sought to further boost tumor immunity in T-Sgk1 −/− mice by vaccination. Mice were immunized with vaccinia virus expressing OVA seven days prior to intravenous injection of B16 melanoma cells expressing OVA, and survival was monitored as the primary outcome. We found that TSgk1 −/− mice had significantly prolonged survival compared to wild-type mice in response to a tumor vaccine (Fig. 7e) . Thus, the targeted deletion of SGK1 in T cells leads to enhanced tumor immunity, characterized by more IFN-γ production and robust immunologic rejection of tumors.
DISCUSSION
A critical task of both the adaptive and innate immune system is to integrate cues from the immune microenvironment and then respond appropriately. Recently, it has become clear that the evolutionarily conserved serine/threonine kinase mTOR plays a central role in this process 15 . The outcome of mTOR activation is determined by the regulation of selective downstream signaling pathways and substrates. To this end, we have identified the AGC kinase SGK1 as an mTORC2 activated substrate that selectively regulates T H 1 and T H 2 helper T cell differentiation. T cells lacking SGK1 demonstrate a markedly diminished ability to differentiate into T H 2 cells both in vitro and in vivo. Furthermore, under T H 2 polarizing conditions the T-Sgk1 −/− T cells inappropriately produced IFN-©. Thus, under T H 2 conditions SGK1 simultaneously promotes T H 2 differentiation while also inhibiting the production of T H 1 cytokines. Likewise, in vivo we observed increased IFN-© production by the T-Sgk1 −/− T cells in the setting of viral infection and anti-tumor immunity. Of note, under T H 1 polarizing conditions in vitro, the T-Sgk1 −/− cells produced equivalent levels of IFN-© as wild-type T cells. Perhaps this indicates that under strongly polarizing conditions in vitro, the ability of SGK1 to inhibit the T H 1 response is inconsequential. However, in vivo, under inflammatory conditions that predominantly favor T H 1 polarization, SGK1 signaling appears to limit the magnitude of the T H 1 immune response.
Our studies provide a mechanism by which mTOR (specifically mTORC2) activation regulates T H 1 and T H 2 differentiation. Recently, it has been reported that SGK1 plays a role in promoting the stability of pathogenic T H 17 cells 12 . Notably, in this study, as in ours, T H 17 differentiation was similar in both wild-type and T-Sgk1 −/− T cells. However, it was shown that SGK1 plays a role in controlling the expression of the IL-23 receptor. As a result, T cells lacking SGK1 respond poorly to IL-23 and T-Sgk1 −/− mice are resistant to the development of experimental autoimmune encephalitis (EAE). Furthermore, it was shown that an increase in the extracellular concentration of sodium leads to increased IL-23-mediated T H 17 differentiation and that this effect was abrogated in T-Sgk1 −/− T cells. This report and another link these findings to the ability of increased dietary salt to exacerbate EAE 12, 13 .
Previous studies on the role of SGK1 in the kidney provided clues as to how this AGC kinase may be functioning in T cells 11 . In order to reclaim sodium in the urine, SGK1 prevents degradation of sodium channels by phosphorylating and inhibiting the NEDD4-2 E3 ubiquitin ligase 5, 6 . Similarly, we found that SGK1 promoted T H 2 differentiation by phosphorylating and inhibiting NEDD4-2, thus preventing degradation of JunB. These findings are consistent with previous reports that mice lacking Ndfip or Itch display a hyper-T H 2 phenotype 26, 27 . In these studies loss of Ndfip or Itch led to accumulation of JunB and increased expression of IL-4. Overall, our studies serve to strengthen the link between mTOR-SGK1 and the regulation of cellular differentiation and function by E3-ligases. Just as these connections have been shown to be important in T cells and renal epithelial cells, we propose that these pathways will prove to be important for a diversity of cellular functions.
Our findings identify SGK1 as a potential target for the treatment of T H 2-mediated autoimmune and allergic diseases, such as asthma. Currently, non-specific immunosuppressive agents such as steroids play an important role in the treatment of acute asthma flares as well as in preventing recurrences [35] [36] [37] . Our data suggest that the selective inhibition of SGK1 might represent an immunomodulatory approach to treating and preventing the sequelae of asthma and other allergic diseases without globally inhibiting the immune system. Interestingly, small molecule inhibitors of SGK1 have already been developed 38, 39 . Additionally, inhibiting SGK1 may be of therapeutic value in terms of enhancing T H 1-mediated immune responses, for example, in the setting of viral infections or as an adjunct to tumor immunotherapy. That is, while an asthmatic might take an SGK1 inhibitor to prevent the development of T H 2-mediated inflammation, the same small molecule inhibitor might be given to a patient in the midst of receiving cancer immunotherapy in order to enhance the anti-tumor response.
Methods
Mice
Mice were kept in accordance with guidelines of the Johns Hopkins University Institutional Animal Care and Use Committee. Mice with loxP-flanked Sgk1 alleles were described previously 11 , and mice with loxP-flanked Rictor alleles were provided by M. Magnuson 40 . C57BL/6, Cd4-Cre and OT-II mice were obtained from Jackson Laboratories and bred to Thy-1.1 backgrounds. 5C.C7 mice were from Taconic Farms.
Antibodies and reagents
The following antibodies for flow cytometry were from BD Biosciences: anti-B220 (RA3-6B2), anti-CD3 (2C11), anti-CD4 (RM4-5), anti-CD8 (Ly-3), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD124 (mIL4R-M1), anti-IFN-γ (XMG1.2), anti-IL-17a (TC11-18H10), and anti-human CD8 (RPA-T8). Anti-CD62L (MEL-14), anti-IL-13 (eBio13A), anti-IL-5 (TRFK5), anti-T-bet (eBio4B10) and anti-Foxp3 (FJK-16s) were from eBioscience.
The following antibodies for immunoblotting were from Cell Signaling Technologies: Antibody to Rictor (2140), NDRG1 phosphorylated at Thr346 (5482), total NDRG1 (9408), antibody to Akt phosphorylated at S473 (4060), pan-Akt (4685), NEDD4-2 phosphorylated at Ser342 (4080), total NEDD4-2 (4013), TCF-1 (2206), antibody to β-catenin (9562), antibody to phosphorylated β-catenin (9561), antibody to phosphorylated STAT6 (9361). Anti-T-bet (4B10) and anti-GATA-3 (TWAJ) were from eBioscience. Anti-JunB (210) was from Santa Cruz Biotechnology. Anti-ubiquitin was and actin were from Sigma. MG132 was from Sigma, PP242 was from Calbiochem, and CFSE was from Invitrogen.
T cell stimulation and polarization
CD4 + T cells were purified by negative selection using a CD4 + isolation kit and MACS Cell Separation (Miltenyi Biotec). For polarizing experiments, T cells were stimulated with irradiated autologous APCs or with plate-bound anti-CD3 and soluble anti-CD28. For APCfree stimulations, flat-bottomed plates were coated with anti-CD3 (3 μg/ml) diluted in PBS, and soluble anti-CD28 (2 μg/ml) was added to the cultures. For stimulation with APCs, T cells were cultured with irradiated APCs and anti-CD3 (1 μg/ml), followed by rest and expansion for 5 days. For rechallenge, live cells were harvested by Ficoll gradient, washed, and then stimulated with plate-bound anti-CD3 (1 μg/ml) and soluble anti-CD28 (2 μg/ml). Polarizing conditions were as follows: T H 0, anti-IL-4 (5 μg/ml) and anti-IFN-γ (5 μg/ml), with IL-2 (1 ng/ml) during the rest period; T H 1, IL-12 (5 ng/ml), IFN-γ (100 ng/ml) and anti-IL-4 (5 μg/ml), with IL-2 (1 ng/ml) during the rest period; T H 2, IL-4 (10 ng/ml), anti-IL-12 (5 μg/ml) and anti-IFN-γ (5 μg/ml), with IL-2 (1 ng/ml) during the rest period; T H 17, IL-6 (30 ng/ml), TGF-β (3 ng/ml), anti-IFN-γ (5 μg/ml), anti-IL-4 (5 μg/ml), and IL-23 (10 ng/ml) during the rest period. Stimulatory anti-CD3 (2C11) and anti-CD28 (37.51), as well as neutralizing anti-IFN-γ (XMG1.2) and anti-IL-4 (11B11) were purified from hybridoma supernatants prepared in-house. Neutralizing anti-IL-12p40 (C17.8) was from eBioscience. Cytokines were from Peprotech.
Adoptive transfer
1 × 10 6 naïve CD4 + T cells specific for the OVA MHC class II epitope (OVA aa329-337) congenically marked with Thy1.1 were transferred intravenously to Thy1.2 C57BL/6 recipients by retro orbital injection. 1 × 10 6 pfu Vac-OVA was simultaneously administered by either retro orbital injection or intraperitoneal injection.
House Dust Mite Asthma Model
On days 0 and 7, mice were primed by intraperitoneal injection of 10 μg of house dust mite (HDM) extract (D. pteronyssinus, Greer Labs) in PBS. On days 14 and 21, mice were challenged via inhalation of 50 μg HDM extract per nostril. On day 24, mice are sacrificed for analysis. Lymphocytes from bronchoalveolar lavage (BAL) and mediastinal lymph nodes were stimulated ex vivo with PMA (phorbol 12-myristate 13-acetate) and ionomycin for 4 h. Lung lymphocytes were stimulated ex vivo with 30 μg HDM extract for 72 h, and supernatant from cultures were analyzed by ELISA. Differential cellular analysis of BAL was done via cytospin and Diff-quick staining. For histological analysis, lungs were formalin fixed, embedded in paraffin, and stained with hematoxylin and eosin, or periodic acid-Schiff (PAS), and scored by previously reported methods 41 . Peribronchiolar and perivascular inflammation was determined by a semi-quantitatively graded scale from 0-3, where a score of 0 = absent inflammation, 1 = mild, 2 = moderate, 3 = severe. Goblet cell hyperplasia was assessed by PAS staining of histologic sections, and was semiquantitatively graded on a scale from 0-3, where a score of 0 = no or rare PAS-positive cells, 1 = less than 10% PAS-positive cells observed at 10×, 2 = between 10% and 25% PAS-positive cells observed at 10×, and 3 = greater than 25% PAS-positive cells observed at 4×. A composite score was determined by multiplying the graded score and the percent of airways or vessels that exhibited a given pathological finding. All scoring was performed by a pathologist (P. Illei), who was blinded to the identity of the samples, and all slides were examined in a random order.
Influenza Model
On day 0, mice were challenged with intranasal influenza strain PR8 (Charles River) by injecting 600 egg infective dose (EID) per nostril for a final dose of 1200 EID. On day 8, mice were sacrificed. Lymphocytes from the lung were harvested by gentle mechanical and chemical digestion of lung parenchyma with collagenase and DNAse and stimulated ex vivo with PMA and ionomycin for 4 h. Experimental samples from groups were excluded from the final analysis if flow analysis of T lymphocytes from lungs demonstrated more than 70% CD44 − and no detectable MHC class I or class II NP tetramer-positive cells, suggesting inadequate influenza inoculation.
B16 melanoma model
Mice were injected with 2 × 10 5 B16-OVA cells intravenously on day 0 and lungs were harvested 21 days later. Lung lymphocytes were stimulated ex vivo with PMA and ionomycin (Sigma) at a concentration of 50 ng/ml and 500 ng/ml, respectively. For survival experiments, mice were injected with 1 × 10 6 pfu VAC-OVA intraperitoneally on day 0, followed by intravenous injection with 2 × 10 5 B16-OVA cells on day 7.
Ovalbumin (OVA) airway sensitization model
OVA (Sigma-Aldrich) was adsorbed by gentle shaking for 30 min onto Imject Alum adjuvant (Pierce) to a final concentration of 250 μg/ml. Mice were primed by intraperitoneal injection of 50 μg of OVA-Alum in 200 μl. On day 7, mice were boosted by the same protocol. On days 15, 16, and 17, mice were challenged with intranasal OVA by injecting 25 μg OVA in PBS per nostril. On day 18, mice were sacrificed.
Intracellular staining
Brefeldin A (GolgiPlug; BD Biosciences) or monensin (GolgiStop; BD Biosciences) was used for cytokine staining. Cell were stained for surface antigens, fixed and made permeable with either the BD Cytofix/Cytoperm or the eBioscience Fixation/Permeabilization kit, then stained for intracellular cytokines. For intracellular staining of phosphorylated proteins, cells were fixed with 2.0% formalin and permeabilized with methanol.
Flow Cytometric Analysis
Flow cytometric data was acquired using a BD FACS Calibur or LSR II, and analyzed using FlowJo7.6 (Tree Star Inc, Ashland, OR). Gates were determined by using unstimulated controls or isotype controls where appropriate. Cells were sorted using a BD FACS Aria at the Flow Cytometry Core at the Sidney Kimmel Comprehensive Cancer Center, JHMI.
Immunoblot analysis
For immunoblot analysis of mTOR substrates, CD4 + T cells were stimulated in regular medium with anti-CD3 (1 μg/ml), anti-CD28 (2 μg/ml) and antibody to hamster immunoglobulin IgG1 (0.75 μg/ml; G94-56; BD Biosciences). T cells were harvested by centrifugation and resuspended in ice-cold lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate (glycerol-2-phosphate), 1 mM sodium orthovanadate, 1 mM PMSF, 1× protease inhibitors (Roche) and lysed at 4 °C for 30 min. Lysates were cleared of debris by high-speed centrifugation. Equal protein mass from each condition was mixed with 4× LDS buffer (Invitrogen) and boiled for 10 min. Lysates were then loaded into NuPAGE gels (10% Bis-Tris gels, Invitrogen) and run at 150 V for 90 min. Protein was transferred to polyvinylidene fluoride (PVDF) membranes with transfer buffer (1× NuPAGE Transfer Buffer (Invitrogen) with 20% methanol) at 30 V for 90 min. Membranes were blocked in 5% nonfat dry milk (NFDM) for 60 min, washed briefly with Tris-buffered saline (pH=8) + 0.1% Tween-20 (TBST) and probed with primary antibody in 4% bovine serum albumin in TBST overnight at 4 °C. Membranes were washed with TBST three times for 10 min and probed with secondary antibody conjugated to horseradish peroxidase (HRP) in NFDM. Membranes were washed 2 times in TBST for 5 min, and then once in Tris-buffered saline once for 5 min. Enhanced chemiluminescent plus substrate (GE Healthcare) was used to detect HRP-labeled antibodies. Blots were developed using a Biospectrum Multispectrum Imaging System and images were acquired and analyzed using VisionWorks, LS Image Acquisition and Analysis software (UVP).
Enzyme-linked immunosorbent assay
IL-2, IL-4, IL-5, and IL-13 were analyzed by enzyme-linked immunosorbent assay as described by the manufacturer (eBioscience). Total serum IgE was measured using the following reagents from BD: anti-mouse IgE capture antibody (553413), mouse IgE standard (557080), and anti-mouse IgE biotinylated detection antibody (553419). HDM and OVA-specific antibodies were analyzed by enzyme-linked immunosorbent assay in NuncImmuno plates which had been coated overnight at 4 °C with 100 μl HDM (25 μg/ml in PBS) or OVA (20 μg/ml in PBS) and blocked for 1 h at 25 °C with assay diluent (eBioscience). Wells were washed several times and mouse serum samples diluted in assay diluent were added for 2 h or overnight. Wells were washed and then biotinylated antimouse immunoglobulin IgG1a (553441; BD) or IgG2a (553455; BD) diluted to a concentration of 0.5 μg/ml in assay diluent was added for 1 h. Wells were washed and then streptavidin-conjugated HRP (eBioscience) was added for 30 min. Wells were washed seven times, and then incubated for 15 min with tetramethylbenzidine substrate, or until the reaction approached saturation. Linear regression analysis or absorbance levels were used to determine antibody titers or relative differences.
Real-time PCR
RNA was isolated and reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's protocol. Primers for short and long isoforms of TCF-1 were from Sigma, and primers to detect NEDD4-2 and Ndfip were from Applied Biosystems. Primers used to detect TCF-1 long isoforms were the following: 5′-caatctgctcatgccctacc-3′ (forward) and 5′-gcctgtgaactccttgcttc-3′ (reverse). Relative amounts of long and short isoforms were quantified using real-time PCR with a SYBR green fluorescent probe (Applied Biosystems). Quantitative RT-PCR was performed using a Step One Plus Real Time PCR System (Applied Biosystems).
Retroviral transduction
T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 (as described above) overnight prior to spinfection with supernatants from 293T Phoenix cells. The Phoenix helper-free retroviral ecotropic packaging cell line (Nolan Laboratory) was transfected using Lipofectamine 2000 (Invitrogen) with plasmids encoding MSCV retrovirus containing full-length TCF-1 and a human CD8 reporter. MSCV constructs were provided by J. Sen.
siRNA knockdown
T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 (as described above) for 48 h prior to transfection. ON-TARGET siRNA reagents for scrambled control and NEDD4-2 and Ndfip specific RNA-mediated interference were from Dharmacon. Nucleofection reagents were from Lonza.
Statistical analysis
Prism version 5.0 (GraphPad Software) was used to perform statistical analyses, including unpaired Student's t-test, 2-way Analysis of Variance (ANOVA), and Log-rank (Mantel Cox) survival analysis. A P-value <0.05 was considered to be statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Supernatants were harvested to determine IL-2 production by ELISA. ND = not detectable. Data are representative of 3 independent experiments (a-g) and samples were analyzed in triplicate in each experiment (g). Statistical significance determined by Student's t-test, NS=No Significance, error bars s.e.m. IL-4, IL-13 and IL-5 production from lung lymphocytes from mice that had been sensitized intraperitoneally and re-challenged intranasally on days 14 and 21 with HDM extract to induce allergic airway inflammation. Lung lymphocytes were stimulated for 3 days ex vivo with HDM extract, and supernatants were harvested and analyzed by ELISA for cytokine production. (d-g) IL-4, IL-13 and IL-5 production from mediastinal lymph nodes from mice that had been immunized as in a-c. Lymphocytes were stimulated ex vivo with PMA and ionomycin for 4 h, then fixed, permeabilised and analyzed by intracellular staining and flow cytometry for cytokine production. (h) Lymphocytes were harvested from lung parenchyma or BAL, stimulated ex vivo with PMA and ionomycin for 4 h, and analyzed for production of IFN-γ by intracellular staining and flow cytometry as described above. (i) As in h, but lymphocytes were harvested from mediastinal lymph nodes. (j-l) Total IgE (j), HDM specific IgE (k), and HDM specific IgG1 (l) in serum from mice that were sensitized and rechallenged with HDM extract as described above. Antibody titers were extrapolated from a standard curve (if available) or absorbance is shown for a dilution of serum for which all samples were in the range of the assay. (m,n) Representative lung sections after periodic acid-Schiff (PAS) (m) or hematoxylin and eosin (H&E) (n) staining for saline control (mock) and HDM-treated mice. Pathologic changes in WT mice include goblet cell hyperplasia (m) and perivascular and peribronchiolar inflammation (n). Images from HDM treated mice are shown at 10× (top, middle rows) and at 20× magnification (bottom row).
(o-p) Histologic scoring data of PAS + cells in large bronchioles (o) and small bronchioles (p) from HDM-treated mice. (q) Histologic scoring data of perivascular and peribronchiolar inflammation as seen in H&E stained lung sections as described above. Data are representative of 3 independent experiments (a-i), 4 independent experiments (j-l) or 2 independent experiments (m-q), n = 5-11 mice per group. (Statistical significance determined by Student's t-test (a-q), **** P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, error bars s.e.m.) 
